Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2006

View Archived Issues

BPC-157 evaluated in model of anastomosis healing

DDP-733 increases lower esophageal sphincter pressure in cats

Cardiome updates progress of RSD-1235 through quarter

Medarex offers overview of inhouse and partnered programs

URB-597 has antidepressant activity in animal models

Cannabinoid receptor 2 a target for osteoporosis

In vitro studies show osteoporosis treatment potential of kobophenol A

Pagoclone produces decrease in severity of stuttering

7TM Pharma acquires CareX

Clinical results support further development of BAY 79-4980 for hemophilia A

EnVivo sets out plans for drug development progression

Proof-of-concept study for NicVAX in smoking cessation

AST-120 studied in North America and Europe for fistulizing Crohn's disease

VQD-002 studied in new phase I/IIa trial for solid tumors

Preclinical safety studies completed for oral calcitonin program

Enrollment completed in MERLIN TIMI-36 study of ranolazine

Second U.S. phase III study of Zadaxin in HCV fails to meet primary endpoint

Eraxis launched in U.S. for antifungal indications

Novel therapeutic agents for respiratory disorders disclosed in recent patent literature

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

New treatment options for inflammatory disorders disclosed

Ganfort approved for glaucoma in E.U.

Iplex now available for primary IGFD

Avastin filed for first-line treatment of metastatic breast cancer

Accelerated approval for Thalomid in multiple myeloma

Seasonique extended-cycle oral contraceptive receives FDA approval

Cubicin approved for S. aureus bloodstream infections

Zostavax approved in U.S. for prevention of shingles

Cannabinoid CB2 receptors as a target for anxiety and substance abuse

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...